Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Warp Speed Companies Grilled On Vaccine Safety, Price And Timelines

Two Companies Commit To Not-For-Profit Supply

Executive Summary

House committee seeks reassurances on a range of issues, including the security of a US vaccines supply chain against a background of rising tensions with China.

You may also be interested in...



Capacity, Expertise Drive Korea's Emergence As COVID-19-Related Manufacturing Base

A series of major COVID-19-related manufacturing deals reached by South Korean firms indicate the country could emerge as a major base for the production of drugs and vaccines.

Pfizer’s US Contract Sets The Financial Bar For COVID-19 Vaccines

The US government’s order of 100 million doses for $1.95bn means the implied price for Pfizer/BioNtech's vaccine is $19.50 per dose. That could set a benchmark for solid near-term revenue and profitability for companies in the space. 

In Case You Missed It …

We clean out your Thanksgiving and Black Friday inbox so you don’t have to. Stories you may have missed over the holidays.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel